uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

Core Insights - uniQure N.V. has received Breakthrough Therapy designation from the FDA for AMT-130, indicating significant progress towards a potential disease-modifying treatment for Huntington's disease [3][4] - The company reported a cash position of approximately $409.0 million as of March 31, 2025, which is expected to fund operations into the second half of 2027 [7] - Financial results for Q1 2025 show a revenue decrease to $1.6 million from $8.5 million in Q1 2024, primarily due to reduced collaboration and contract manufacturing revenues [8] Company Developments - AMT-130 is advancing towards a planned Biologics License Application (BLA) submission, with regulatory updates expected in Q2 2025 [3][4] - Initial safety data from the third cohort of the Phase I/II study of AMT-130 indicate it is generally well-tolerated, with no treatment-related serious adverse events reported [5][6] - The company plans to present initial clinical data for AMT-260 at the Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 [4][9] Financial Highlights - The cash position increased from $367.5 million at the end of 2024 to $409.0 million by March 31, 2025, largely due to net proceeds of $80.5 million from a follow-on offering [7] - Research and development expenses decreased to $36.1 million in Q1 2025 from $40.7 million in Q1 2024, reflecting a reduction in employee-related and facility expenses [11] - The net loss for Q1 2025 was $43.6 million, or $0.82 per share, compared to a net loss of $65.6 million, or $1.36 per share, in the same period of 2024 [16][25]